Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan Nov 26, 2019
Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference Oct 17, 2019
Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update Oct 7, 2019
Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes Sep 18, 2019
Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065 Sep 17, 2019
